SCHEDULE 13G/A: JPMorgan Chase & Co. Reports Zero Beneficial Ownership in Revance Therapeutics, Inc.

JPMorgan Chase & Co. has filed an amended Schedule 13G, indicating that its beneficial ownership in Revance Therapeutics, Inc. has fallen to 0.0%.

Summary

• JPMorgan Chase & Co. filed an Amendment No. 1 to Schedule 13G concerning its beneficial ownership in Revance Therapeutics, Inc.
• The filing states that JPMorgan Chase & Co. beneficially owns 0.0% of Revance Therapeutics, Inc.'s Common Stock.
• This includes 0 shares with sole voting power, 0 shares with shared voting power, 0 shares with sole dispositive power, and 0 shares with shared dispositive power.
• The event requiring this filing occurred on February 28, 2025.
• J.P. Morgan Markets Ltd and J.P. Morgan Securities LLC are identified as relevant subsidiaries of JPMorgan Chase & Co. in relation to this filing.
• JPMorgan Chase & Co. certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual report of a change in beneficial ownership, indicating a neutral sentiment as it does not contain performance or strategic updates.

Key Dates

Keywords

Revance Therapeutics, Inc., JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership